Chardan Capital analyst Keay Nakae maintained a Buy rating on Lineage Cell Therapeutics (LCTX) today and set a price target of $4.00.
The post Lineage Cell Therapeutics (LCTX) Receives a Buy from Chardan Capital appeared first on Smarter Analyst.
Chardan Capital analyst Keay Nakae maintained a Buy ...

https://www.smarteranalyst.com/new-blurbs/lineage-cell-therapeutics-lctx-receives-a-buy-from-chardan-capital/

#SmarterAnalyst